Standard Retention Enema ofQu-Yu Tong-Bi Decoction on Inflammatory Mediators and Hemorrheology among Chronic Prostatitis Cases / 世界科学技术-中医药现代化

ABSTRACT

Through observation on changes of inflammatory mediators and hemorrheology among chronic prostatitis patients before and after treatment, this study was aimed to compare the therapeutic differences between the applications of standard retention enema ofQu-Yu Tong-Bi (QYTB) decoction andα-blockers combined with quinolones. During the same period, 164 patients of the Henan Province of Traditional Chinese Medicine Hospital were randomly divided into the observation group and control group, with 62 cases in each group. Retention enema of QYTB decoction was given in the observation group; andα-blockers combined with quinolones were used in the control group. The treatment course was one month. And the differences were compared. The results showed that the total effective rate of the observation group was 79.03% (49 cases); and that of the control group was 61.29%(39 cases). There was statistical significance between two groups (P < 0.05). There was statistical significance on TNF-α, IFN-γ and NIH-CPSI score comparison before and after treatment of two groups (P < 0.05). Compared to the control group, the posttreatment TNF-α, IFN-γ and NIH-CPSI score in the observation group had significant difference (P < 0.01). There were no significant differences on the whole blood viscosity (high shear), plasma viscosity and erythrocyte deposited test value contrast between pretreatment and posttreatment in the control group. There were significant differences on the whole blood viscosity (high shear) and plasma viscosity between pretreatment and posttreatment in the observation group (P < 0.05). However, there was no significant differences on erythrocyte deposited test value contrast. It was concluded that both methods had certain therapeutic effect in the treatment of chronic prostatitis. However, the effect of retention enema of QYTB decoction was better than the treatment of quinolones combined withα-blockers.